01. Doctor Overview
Dr. James Stevenson is a medical oncologist and hematologist at the Cleveland Clinic located in Cleveland, Ohio. Dr. Stevenson joined the staff at the Cleveland Clinic in 2012 and in July of 2015 he was appointed Vice Chairman of the Department of Hematology and Medical Oncology.
Dr. Stevenson is part of a team of experts at the Cleveland Clinic’s Taussig Cancer Institute that employs a multidisciplinary approach to the care of patients with lung cancer and mesothelioma. He is responsible for organizing the Multidisciplinary Pleural Mesothelioma Center at the Taussig Cancer Institute where medical and radiation oncologists, pulmonologists, thoracic surgeons, pathologists, and palliative care experts deliver quality care to patients and offer innovative treatments based on the latest research. The goal of the center is to streamline and shorten the time to diagnosis for its patients. Dr. Stevenson’s degree of expertise in his field, as well as his compassion for his patients, is reflected in online reviews by his patients who have said “I would not be alive without Dr. Stevenson and the level of care and concern he has given me” and “…Dr. Stevenson helped save my life and I could not be happier about that.”
02. Fast Facts
Doctor Fast Facts
Main Specialty: Internal Medicine, Medical Oncology
Other Interests & Specialties: Cancer, lung cancer, mesothelioma, thymic cancer, colorectal cancer, blood disorders, sarcoma, myeloma, lymphoma, chemotherapy, thymic tumors and thymoma.
Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, Philadelphia Magazine Award, member of the American Society of Clinical Oncology
Education & Experience:
- Fellowship for Hematology and Medical Oncology at Thomas Jefferson University Hospital
- Residency for Internal Medicine at the Thomas Jefferson University Hospital
- Internship for Medicine at the University of Florida College of Medicine – Shands Medical Center
- Medical Degree from Jefferson Medical College of Thomas Jefferson University
- Undergraduate study at the University of Notre Dame
The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma. OncoTargets and Therapy. November 2016;9:7247-7252. doi: 10.2147/OTT.S100214
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clinical Cancer Research. August 2016;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133
Current issues in malignant pleural mesothelioma evaluation and management. The Oncologist. September 2014;19(9):975-84. doi: 10.1634/theoncologist.2014-0122
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. Journal of Clinical Oncology. July 2012;30(20):2509-15. doi: 10.1200/JCO.2011.41.5869
Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. August 2014;2(8):e26218. doi: 10.4161/onci.26218
04. Mesothelioma Clinical Trials
Mesothelioma Clinical Trials by James Stevenson, M.D.
Dr. Stevenson is associated with the following clinical trials: